Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

PSYCHCNVS · Copy number variations conferring risk of psychiatric disorders in children

FP7Status: CLOSED1 January 200930 June 2012EU funding €2,999,798

The recent technical improvements for the study of the cytogenetic basis of disease have led to the identification of many microdeletion and microduplication syndromes. De novo copy number variants (CNVs) are seen more often than expected in autistic patients, and rare chromosomal aberrations are known to account for a small fraction of schizophrenia and bipolar disorder. Recurrent spontaneous mutations at multiple sites across the genome may be a prime cause of these disorders, and the reduced fertility associated particularly with autism and schizophrenia may, through selection pressure, maintain these variants at very low frequency. CNVs are large enough to be identified using cost efficient genome-wide search techniques, such as oligonucleotide arrays. In contrast, rare DNA mutations might confer a large proportion of the overall genetic risk, but cannot be easily identified at the present time. Genetic epidemiology suggests that autism, bipolar disorder, and schizophrenia are highly heritable and share susceptibility genes. However, the results of dense SNP array-based genome wide association scans for these disorders have been disappointing, as no high frequency risk alleles have been identified. The PsychCNVs consortium will apply oligonucleotide arrays for the large-scale interrogation of CNV variation in the human genome, focusing on people with autism and childhood onset schizophrenia and bipolar disorder, where CNVs are likely to be more common. This project follows on logically from our hypothesis-independent genome-wide SNP search for common variants, we now intend to systematically search for large, rare CNVs conferring high risk. The genetic risk conferred by CNVs will be estimated by genotyping samples from 2800 patients, to identify de novo or recent spontaneous mutations. Until low cost whole genome sequencing becomes available this approach offers the best current hope to identify causative genomic variants for these disorders.

Consortium · 8 organisations

coordinator

ISLENSK ERFDAGREINING EHF

IS · €761,558

participant

INSTITUT ZA MENTALNO ZDRAVLJE

RS · €240,600

participant

NATIONAL RESEARCH CENTER OF MENTAL HEALTH - RUSSIAN ACADEMY OF MEDICAL SCIENCES

RU · €545,400

participant

UKRAINE RESEARCH INSTITUTE OF SOCIAL AND FORENSIC PSYCHIATRY AND DRUG ABUSE OF THE MINISTRY OF HEALTH

UA · €240,600

participant

LANDSPITALI UNIVERSITY HOSPITAL

IS · €160,500

participant

Tbilisi State Medical University

GE · €240,600

participant

UNIVERSITY CLINIC OF PSYCHIATRY

MK · €240,600

participant

KING'S COLLEGE LONDON

UK · €569,940

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.